Overview Our mission is to create a world without infectious disease. Corticosteroids and other drugs are also being used to treat hospitalized patients. Initial results for this arm of the BLAZE-4 trial are expected in the first half of 2021. We term this approach "immune programming." 8226; Acquiring or accessing new technology platforms and assets. 11 VIR-7832 for COVID-19 Molecular Characteristics. Immunologic parameters, such as T-cell responses to SARS-CoV-2, will also be examined. 13 VIR-2218 for HBV Molecular Characteristics. HBV DNA can become integrated into human DNA as intDNA. The current trial design of VIR-2218-1001 is shown below. Arrows indicate trial progression. This trial currently has completed enrollment of 81 subjects across all three parts. The primary endpoints across Parts A-C of the trial are safety and tolerability. All cohorts have completed dosing and have completed follow-up. The biologic activity of VIR-2218 was assessed by declines in HBsAg. VIR-3434 specifically targets the antigenic loop, or AGL, on HBsAg. Second, VIR-3434 has the potential to act via ADCC. Parts B and C are single ascending dose designs in patients with chronic HBV on NRTIs. We anticipate initial clinical data in the second quarter of 2021. Vaccine for HIV Prophylaxis Summary We are developing a vaccine to prevent HIV. Each line represents a different NHP. We initiated a Phase 1 clinical trial for VIR-1111 in December 2020. mAb potency and breadth are based on the epitope bound, affinity of binding and valency. This platform may also identify targets relevant to diseases outside of infection. These nodes are represented as dots interconnected with a dense network of lines. These technologies are used in our VIR-2482 and VIR-3434 product candidates. In addition, the term of the HIV grant agreement was extended through December 31, 2021. Convalescent plasma is also available under EUA. These so-called Phase 4 trials may be made a condition to approval of the application. We are not currently a party to any material legal proceedings. An investment in shares of our common stock involves a high degree of risk. We have no prior experience in these areas. We do not currently have the ability to independently conduct any clinical trials. We expect to control only certain aspects of our CROs' activities. In addition, there is a natural transition period when a new CRO commences work. We may be required to indemnify collaborators or contractors against such claims. Further, we may not be able to obtain adequate remedies for any breach. In addition, our clinical trials have been affected by the ongoing COVID-19 pandemic. Such a notice could further harm our reputation and our ability to compete. However, we are no longer an emerging growth company as of December 31, 2020.
